Tenlimax-M500 Tablets

• A novel DPP-4 inhibitor with a preferable profile in terms of long-term efficacy and safety.
• Provides strongest binding to DPP-4 enzymes as compared to other gliptins.
• Gives potent and sustained effects on glycemic control and reduces diabetic complications.
•  Provides cardioprotection by improving left ventricular function and endothelial dysfunction without QT prolongation. Int J Basic Cin Pharmacol 2016:52):229-234
• Effectively improves B-cell function and decreases insulin resistance.
• Normalizes daily blood glucose fluctuations by suppressing post-prandial hyperglycemia at all three meals daily.
• Shows significant improvement in lipid profiles along with improvement in blood glucose & HbA1c level.
• Effectively Enhances adiponectin levels to regulate insulin sensitivity & energy homeostasis.
• Teneligliptin 20 mg once daily is more potent than voglibose 0.2 mg tid, or vildagliptin 50 mg qd
• Does not require dose adjustment for diabetic patients with end-stage renal disease and in hepatic patients.